Intech Investment Management LLC Has $3.85 Million Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Intech Investment Management LLC grew its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 370.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,221 shares of the specialty pharmaceutical company’s stock after buying an additional 24,582 shares during the quarter. Intech Investment Management LLC’s holdings in Jazz Pharmaceuticals were worth $3,845,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of JAZZ. IFP Advisors Inc bought a new stake in Jazz Pharmaceuticals during the fourth quarter worth about $25,000. Jones Financial Companies Lllp increased its position in shares of Jazz Pharmaceuticals by 75.1% during the 4th quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company’s stock worth $37,000 after purchasing an additional 130 shares during the last quarter. UMB Bank n.a. raised its stake in shares of Jazz Pharmaceuticals by 70.9% during the 4th quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock worth $38,000 after purchasing an additional 129 shares in the last quarter. Lindbrook Capital LLC boosted its holdings in shares of Jazz Pharmaceuticals by 82.6% in the 4th quarter. Lindbrook Capital LLC now owns 389 shares of the specialty pharmaceutical company’s stock valued at $48,000 after buying an additional 176 shares during the last quarter. Finally, Itau Unibanco Holding S.A. grew its stake in shares of Jazz Pharmaceuticals by 63.2% in the third quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company’s stock valued at $49,000 after buying an additional 172 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Stock Up 1.8 %

Shares of JAZZ opened at $142.07 on Thursday. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $148.06. The firm has a market cap of $8.63 billion, a P/E ratio of 20.01, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44. The firm’s 50-day simple moving average is $130.66 and its 200 day simple moving average is $121.32. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26.

Wall Street Analysts Forecast Growth

JAZZ has been the topic of several analyst reports. Cantor Fitzgerald lowered shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and upped their price target for the stock from $140.00 to $150.00 in a research report on Wednesday, February 26th. Royal Bank of Canada dropped their target price on shares of Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating on the stock in a report on Wednesday, February 26th. Barclays reissued an “overweight” rating and set a $200.00 price target (up previously from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. JPMorgan Chase & Co. raised their price objective on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. Finally, Morgan Stanley reissued an “overweight” rating and set a $183.00 target price (up from $175.00) on shares of Jazz Pharmaceuticals in a report on Friday, March 7th. One equities research analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Jazz Pharmaceuticals presently has an average rating of “Buy” and an average target price of $187.71.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,800 shares of the business’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $144.87, for a total value of $550,506.00. Following the completion of the sale, the executive vice president now owns 33,318 shares of the company’s stock, valued at $4,826,778.66. The trade was a 10.24 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Bruce C. Cozadd sold 1,500 shares of the business’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total transaction of $185,145.00. Following the completion of the sale, the chief executive officer now directly owns 425,525 shares of the company’s stock, valued at $52,522,550.75. This represents a 0.35 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 28,736 shares of company stock worth $4,022,825. Insiders own 4.20% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.